Formycon and Bioeq say resubmission of the biologics license application for their ranibizumab candidate will not affect launch timing in US or European markets.
In an update on development of a ranibizumab biosimilar candidate, FYB201, for the treatment of macular degeneration, Formycon said it is hoping the FDA will grant approval for large-scale commercialization of the agent and that the approval process will be simplified.
In February, Formycon and its licensing partner, Bioeq, said the FDA had requested additional information related to a manufacturing change and that it would require resubmission of the application for FYB201. A piece of equipment was shifted to a new location, and the change was unrelated to product quality or other product characteristics, Formycon and Bioeq said.
The processing equipment had been moved based on the request of European health authorities, and because of this, the FDA requested additional manufacturing data to support the biologics license application (BLA). The BLA was withdrawn while these data were generated.
The companies are aiming at the market for the Lucentis reference product. Lucentis is a Roche product and garnered sales of $1.12 billion in the third quarter of 2020, down 14% from the year-ago comparable quarter.
In the update, Formycon and Bioeq said they had adjusted their resubmission strategy for FYB201 and intended to file the application with the FDA sometime in the first half of 2021. They said the delay was not expected to have any effect on timing for the launch for FYB201 in the United States or European Union.
Ranibizumab is used to treat wet age-related macular degeneration, a disease that causes excessive formation of blood vessels in the retina of the eye, resulting in a progressive loss of central vision, severe visual impairment, or blindness.
Ranibizumab is also used in the treatment of diabetic macular edema, diabetic retinopathy, myopic choroidal neovascularization, and macular edema following retinal vein occlusion.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.